撰文丨王聪 编辑丨王多鱼 排版丨水成文 抗生素耐药性 已成为全球公共卫生的严峻挑战。世界卫生组织 （WHO） 将其列为人类面临的十大公共卫生威胁之一。随着"超 级细菌"的蔓延，传统抗生素正节节败退，寻找具有全新作用机制、细菌难以产生抗药性的候选药物，成为医学界迫在眉睫的挑战。 当传统抗生素逐渐失效，科学家们将目光投向了自然界中存在数百万年、几乎不产生耐药性的 抗菌肽 （A ntimicrobial Peptide， AMP ） 。然而，传统的抗菌肽挖掘方法高度依赖已知多肽的序列相似性，可能错失了大量未被发现的、演化上距离遥远但功能强大的"宝藏"。 | 2026 年 3 月 | 3 日， | 香港中文大学 | 李煜 | 教授 | | --- | --- | --- | --- | --- | | 团队、 | | 中国科学院深圳先进技术研究院 | | | | 戴磊 | 研究员团队合作 | （ | | 余沁 | | 泽 | 、 | 刘红宾 | 、 | | | 施海梅 | 为论文共同第一作者） | | ，在 Nature 子刊 | | | Nature Biomedical Engineering | | 上发表了题 ...

Core Viewpoint - Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Hanyu Pharmaceutical") expects significant revenue growth in 2025, with projected revenue between 950 million to 980 million yuan, representing an increase of 60.96% to 66.05% year-on-year, and a net profit of 40 million to 50 million yuan, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates 2025 revenue of 950 million to 980 million yuan, a year-on-year growth of 60.96% to 66.05% [1] - Net profit is projected to be between 40 million to 50 million yuan, indicating a return to profitability [1] Group 2: Business Development - The growth in revenue is driven by the synergy between international formulations and active pharmaceutical ingredients, which are core engines of revenue growth [1] - The CRDMO (Contract Research, Development, and Manufacturing Organization) business is being actively advanced, contributing to the company's growth strategy [1] Group 3: Research and Innovation - Hanyu Pharmaceutical maintains a strong focus on innovation, with high R&D investment aimed at developing peptide innovative drugs, complex formulations, and cutting-edge technology platforms [1] - Significant progress has been made in multiple research projects, including the three-target innovative drug HY3003 and semaglutide, reinforcing the company's technological barriers [1] Group 4: Strategic Partnerships - The company is expanding its growth avenues through CRDMO business, leveraging its multi-national GMP certification and full industry chain capabilities [1] - Collaborations with companies like Carbon Cloud Peptide and Borui Pharmaceutical have been deepened, covering projects in areas such as antimicrobial peptides and oral peptides, successfully transforming technical accumulation into systematic service output capabilities [1]

Core Viewpoint - Bacterial pneumonia poses a significant global health burden with high morbidity and mortality, particularly among immunocompromised individuals, necessitating innovative treatment strategies to combat multidrug-resistant (MDR) bacteria and reduce inflammation-induced lung damage [1][2]. Group 1: Current Treatment Challenges - The first-line treatment for bacterial pneumonia primarily relies on empirical antibiotic use, including fluoroquinolones, β-lactams, and macrolides, but clinical efficacy is increasingly compromised by the rise of MDR bacteria, which are present in over 25% of pneumonia cases and are closely associated with increased mortality [1][3]. - Deficiencies in bacterial clearance lead to excessive inflammation, damaging tissue recovery and weakening the host's immune defense, creating significant barriers to effective treatment interventions [1]. Group 2: Innovative Research Findings - A research team from the Icahn School of Medicine at Mount Sinai has developed a novel approach using antimicrobial peptide delivery via peptibody mRNA in anti-inflammatory lipid nanoparticles to treat MDR bacterial pneumonia [2][3]. - Antimicrobial peptides (AMPs) are crucial components of innate immune defense against microbes, offering broad-spectrum activity and effectiveness against MDR bacteria, but their application has been limited by delivery efficiency and therapeutic challenges [4]. - The study utilized a peptibody (PB) based on the LL37 antimicrobial peptide, which can be cleaved by host immune cell-secreted proteases at the infection site, releasing active antimicrobial peptide fragments and enhancing immune cell phagocytic capabilities [4][6]. Group 3: Experimental Results - In a model of MDR pneumonia, a single intratracheal administration of TS41S LNP-PB9 mRNA significantly alleviated weight loss due to infection, markedly improved survival rates in mice, and effectively cleared pulmonary pathogens, outperforming the FDA-approved antibiotic ciprofloxacin [6]. - The treatment demonstrated good safety profiles, with no significant liver or kidney toxicity or immune stress responses observed in repeated dosing experiments, and achieved efficient mRNA delivery in human lung tissues, enhancing antibacterial capabilities in human macrophages [6].

Core Viewpoint - The article discusses the urgent need for new antimicrobial peptides (AMPs) as promising alternatives to traditional antibiotics, particularly in the context of combating multidrug-resistant bacteria, highlighted by the WHO's ESKAPE list, with carbapenem-resistant Acinetobacter baumannii (CRAB) being a primary concern [2]. Group 1: Research Development - A research team from Shandong University published a study in Nature Microbiology on October 3, 2025, focusing on a generative artificial intelligence approach for discovering AMPs against multidrug-resistant bacteria [3]. - The study developed a pre-trained protein large language model (LLM) named ProteoGPT, which efficiently explores the AMP space to address clinical superbugs [4][10]. Group 2: Methodology and Findings - ProteoGPT was further developed into specialized sub-LLMs to create a workflow capable of rapidly screening millions of peptide sequences for strong antibacterial activity while minimizing cytotoxic risks [7]. - In vitro experiments showed that both discovered and generated AMPs exhibited low susceptibility to resistance development in CRAB and methicillin-resistant Staphylococcus aureus (MRSA) [8]. - In animal models, these AMPs demonstrated treatment effects comparable to or better than clinically used antibiotics without causing organ damage or disrupting gut microbiota [8].